Albert Selva O'Callaghan

I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital.

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Sistémicas

Vall Hebron Institut de Recerca

Medicina Interna

Hospital General

Albert Selva O'Callaghan

Instituciones de las que forman parte

Investigador/a principal
Enfermedades Sistémicas

Vall Hebron Institut de Recerca

Medicina Interna

Hospital General

I've been a doctor for over 30 years now and I work at the Vall d'Hebron University Hospital.

Was born in Barcelona on May 1st, 1959. He obtained his medical degree at the University Autonomous of Barcelona in 1982, and so he did also the Doctoral Thesis at the same University in 1992. Since 2010 he is Associated Professor of Medicine, since june 2021 Full Professor. He attended to the internal resident program (MIR) at the Internal Medicine Department at Vall d’Hebron General Hospital in Barcelona from 1986 to 1990, and currently is working as a Senior Consultant and as Head at the Systemic Autoimmune Diseases Unit at the same hospital. He has been focused to the study of idiopathic inflammatory myopathy for more than 25 years and has published several relevant articles and book chapters on the field. Taking care of the patients, teaching at the University and doing research are the three main activities in regard to myositis patients he is committed to.

Líneas de investigación

Cancer and myositis. Relevance of the anti-p155 antibodies and importance of the screening for cancer by Positron Emission Tomography and Computed Tomography (PET/CT).

Anti-p155 antibodies seem to be useful for the diagnosis of paraneoplastic myopathies. We have studied their prevalence and their diagnosis value in a cohort of 137 patients with inflammatory myopathies and we have observed that they have a high negative predictive value. On the other hand, the screening by PET/TC does not contribute much to the conventional screening of cancer in these patients.

IP: Albert Selva O'Callaghan

Proyectos

Autoinmunitat i Malaltia Trombotica

IP: Albert Selva O'Callaghan
Colaboradores: -
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 0.01
Referencia: 2017SGR01129
Duración: 01/01/2017 - 31/12/2020

Identificación de nuevos antígenos en pacientes con miopatía inflamatoria

IP: Albert Selva O'Callaghan
Colaboradores: Ernesto Trallero Araguas
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 121000
Referencia: PI15/02100
Duración: 01/01/2016 - 30/11/2020

Autoimmunitat i Malaltia Trombòtica (GRC)

IP: Miguel Vilardell Tarres
Colaboradores: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, José Ángel Bosch Gil, Josefina Cortes Hernandez, Fernando Martínez Valle, Albert Selva O'Callaghan, Cristina Solé Marce
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación:
Referencia: 2014 SGR 329
Duración: 01/01/2014 - 31/12/2016

Proteinas TIF1 y dermatomiositis paraneoplásicas

IP: Ernesto Trallero Araguas
Colaboradores: Vicente García-Patos Briones, Berta Ferrer Fábrega, Albert Selva O'Callaghan, Gloria Aparicio Español
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 121000
Referencia: PI12/01320
Duración: 01/01/2013 - 31/12/2016